Showing results (11-20 of 53) with videos related to
Sort By:
Pageof 6
Urologic Oncology|November 28, 2016
Emerging role of immunotherapy in urothelial carcinoma-Advanced diseaseMatthew Zibelman, Chethan Ramamurthy, Elizabeth R PlimackTherapeutic Advances in Medical Oncology|August 8, 2018
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?Pooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.Current Opinion in Urology|July 20, 2022
The past, present, and future of pT0 in bladder cancer clinical trialsJared P Schober, Elizabeth Plimack, Daniel M Geynisman, et al.European Urology Focus|May 20, 2019
First-line Immunotherapy in Metastatic Urothelial CarcinomaPooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.Current Treatment Options in Oncology|February 18, 2017
Checkpoint Inhibitors for the Treatment of Renal Cell CarcinomaPooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional SolutionsSuzanne Cole, Matthew Zibelman, Erin Bertino, et al.Journal of Palliative Medicine|April 12, 2014
Assessing prognostic documentation and accuracy among palliative care cliniciansMatthew Zibelman, Qun Xiang, Sandra Muchka, et al.Immunotherapy|June 29, 2016
Checkpoint inhibitors for renal cell carcinoma: current landscape and future directionsMatthew Zibelman, Pooja Ghatalia, Daniel M Geynisman, et al.Ophthalmic Surgery, Lasers & Imaging Retina|March 21, 2019
Pars Plana Vitrectomy Alone for Primary Rhegmatogenous Retinal Detachments Associated With Inferior Breaks in Phakic EyesKatherine E Talcott, Anthony Obeid, Xinxiao Gao, et al.Case Reports in Oncology|March 30, 2022
Clinical Utility of Liquid Biopsy to Identify Genomic Heterogeneity and Secondary Cancer Diagnoses: A Case ReportGregory Hemenway, Marni B Tierno, Reza Nejati, et al.Pageof 6